Benzinga Pro data, Tango Therapeutics (NASDAQ:TNGX) reported Q3 sales of $6.92 million. Earnings fell to a loss of $29.05 million, resulting in a 16.86% decrease from last quarter. In Q2, Tango Therapeutics brought in $5.77 million in sales but lost $24.86 million in earnings.

Why Is ROIC Significant?

Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company's ROIC. A higher ROIC is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROIC suggests the opposite. In Q3, Tango Therapeutics posted an ROIC of -10.96%.

Keep in mind, while ROIC is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.

For Tango Therapeutics, a negative ROIC ratio of -10.96% suggests that management may not be effectively allocating their capital. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.

Analyst Predictions

Tango Therapeutics reported Q3 earnings per share at $-0.33/share, which did not meet analyst predictions of $-0.32/share.

This article was generated by Benzinga's automated content engine and reviewed by an editor.